Ottawa, Canada – Health Canada has authorized the first generic version of semaglutide, a widely popular GLP-1 diabetes treatment, making Canada the first G7 nation to do so. The approval, announced on April 28, 2026, marks a significant step towards enhancing accessibility and affordability of this crucial medication for type 2 diabetes patients. The generic injectable medication is manufactured by Dr. Reddy’s Laboratories.
The approved generic semaglutide is intended for the once-weekly treatment of type 2 diabetes in adults, mirroring the indications of brand-name Ozempic from Novo Nordisk. "The approval of our generic semaglutide injection by Health Canada represents a significant milestone in our GLP-1 journey," stated Erez Israeli, CEO of Dr. Reddy’s Laboratories, emphasizing the company's commitment to expanding access to affordable treatments. In India, Dr. Reddy's sells the drug under the brand name "Obeda."
This development is expected to dramatically reduce treatment costs, as generic medications typically range from 45 to 90 percent cheaper than their brand-name counterparts. Many patients without comprehensive drug coverage have eagerly awaited a more affordable option, given that Ozempic can cost hundreds of dollars monthly. Mina Tadrous, a pharmaceutical policy expert at the University of Toronto, noted that the first generic could cost 75 to 85 percent of the brand name, with prices dropping further as more generic options enter the market.
Health Canada is currently reviewing eight additional submissions for generic semaglutide from various companies. The department highlighted that its review ensured the complex synthetic product is pharmaceutically equivalent to the brand-name biologic drug, maintaining safety, efficacy, and quality standards. While approved for diabetes, semaglutide is also frequently prescribed off-label for weight loss, a factor that has driven its immense popularity.
The Canadian decision could establish a precedent for other G7 countries grappling with the high costs of GLP-1 agonists and the increasing demand for these drugs. Industry analysts predict that this move will introduce significant competition, potentially impacting global pharmaceutical pricing and market dynamics for Novo Nordisk and other manufacturers in the GLP-1 segment. The availability of generic options is anticipated to have a positive impact on both patients and the healthcare system through potential cost savings.
